1 From the Division of Endocrinology, Diabetes and
Clinical Nutrition, Department of Medicine, Oregon Health & Science University,
Portland, OR
See corresponding articles on pages 1103 and 1142.
2 Reprints not available. Address
correspondence to WE Connor,Division of Endocrinology, Diabetes and
Clinical Nutrition,Department of Medicine, L465, Oregon Health &
Science University,Portland, OR 97239-3098. E-mail: connorw@ohsu.edu
.
Alzheimer disease is devastating both to the afflicted personand
to that person's family. Capable persons become helplessand must be
cared for by the family and by the community. Thiscommon problem of
aging will expand in the near future becausepeople are living
longer. It is estimated that 2040%of the population now over the
age of 85 y may have Alzheimerdisease (1). A
further daunting statistic is that, once Alzheimerdisease is
identified as the cause of cognitive decline, thepatient may live
for many years with a high yearly cost of care.Are there potential
and safe measures that would prevent thisslide into cognitive
failure? Fish and fish oil contain 2 fattyacids, docosahexaenoic
acid (DHA) and eicosapentaenoic acid(EPA), that may have promise.
The major dietary sources of these2 fatty acids are fish and
shellfish, from both salt water andfresh water. DHA can also be
synthesized in the body from then3 fatty acid
-linolenic
acid (18:3), which is presentin some vegetable oils and some nuts
and seeds. However, thissynthetic step is relatively inefficient.
DHA is 22 carbons long and has 6 double bonds with the n3
configuration. It is the most prominent fatty acid in the brain,
retina, and spermatozoa (2) and is necessary for vision,
cognition,and sperm motility. DHA is especially rich in the neurons
andsynaptosomes of the cerebral cortex, where it occupies the no.2 position of membrane phospholipids. In premature infants whoseformula contained DHA balanced with n6 arachidonic acid,
vocabulary and motor performance increased and vision improved(3).
Monkeys deficient in dietary n3 fatty acids havereduced vision,
abnormal electroretinograms, and greater amountsof stereotypic
behavior and polydypsia. Of interest also isthe fact that dietary
DHA can be incorporated into monkey brainphosophilipids later in
life as well as during development (4).However,
the brains of Alzheimer disease patients have a lowercontent of DHA
in the gray matter of the frontal lobe and hippocampusthan do the
brains of persons without Alzheimer disease (5).
The brains of persons with Alzheimer disease have an amyloidprotein
complex and an inflammatory component.
With this background, a logical question is: "Would fish consumptionretard the decline in cognitive function that might otherwise
occur in an elderly population, which is subject to Alzheimer
disease? " Fish and fish oil have a high content of DHA andits
20-carbon precursor EPA. Studies to answer this questionwere begun
in the 1990s. In a typical study, the investigatorsestimated the
amount of fish in the diet or measured the compositionof the plasma
fatty acids at baseline, which provided an indexof fish consumption.
Cognition was estimated at baseline witha follow-up years later to
correlate any change in cognitionwith the baseline fish consumption,
plasma fatty acids, or both.In the past, some studies were positive
and some were negative.A recent report from the Framingham Heart
Study showed thatpersons with plasma phosphatidylcholine DHA in the
top quartileof values had a significantly (47%) lower risk of
developingall-cause dementia than did those in the bottom quartile (6).Significantly (P = 0.04) greater protection was obtained fromconsuming 2.9 fish meals per week than from consuming 1.3 fish
meals per week. Two additional positive studies are describedin this
issue of the Journal (7, 8).
In the Zutphen Elderly Study (7), initial data were
obtainedfrom 210 men aged 7089 y. Fish consumption and cognitivefunction were measured in 1990 and 1995, and fish consumershad
less cognitive decline than did fish nonconsumers. A linearrelation
was found between the estimated intake of DHA and EPA(DHA+EPA) and
the prevention of cognitive decline. A DHA+EPAintake of
380 mg/d
seemed to prevent cognitive decline. Thisamount of DHA+EPA would be
found in 20 g Chinook salmon or in100 g cod. Two to three meals of
fish per week would supply380 mg
EPA+DHA/d.
The Minneapolis study of 2251 white men and women began in 198789
with analyses of plasma fatty acids in cholesterol esters and
phospholipids (8). Three neuropsychological tests were givenat baseline and again between 1990 and 1992 and between 1996
and 1998. The risk of decreased global cognition was greaterwith
higher concentrations of palmitic acid and arachidonicacid (20:4n6)
in both cholesterol esters and phospholipids.In contrast, the risk
of cognitive decline was lower with ahigher concentration of
linoleic acid (18:2n6). Cognitivedecline was associated with lower
plasma n3 fatty acids(DHA+EPA) in the subgroup of subjects with
hypertension anddyslipidemia, but this association was not found for
the entiregroup.
In each of these studies, the n3 fatty acids retardedthe decline
in cognition over time. One mechanism for the positiveeffect could
be the antithrombotic and antiinflammatory propertiesof EPA (9).
Moreover, the entrance of DHA into the brain couldcorrect DHA
deficiency in membrane phospholipids in the cerebralcortex in
patients with Alzheimer disease (5), and EPA would
counter the proinflammatory action of arachidonic acid, whichis a
precursor of cytokine and proinflammatory eicosanoids thatmay be
associated with greater cognitive decline. The associationof
palmitic acid in the plasma cholesterol esters and phospholipidsis
of interest. This 16-carbon saturate is associated with thrombosis
and the elevation of plasma LDL cholesterol that can lead to
atherosclerotic obstruction. Both of these conditions couldincrease
the tendency to develop dementia.
Along with numerous previous studies, the Zutphen and Minneapolis
studies provide the rationale for a future clinical trial offish,
fish oil, or both in elderly patients prone to the developmentof
Alzheimer disease. Such a trial would involve blood measurementsof
fatty acids in the plasma and in the red blood cells (redblood cells
are more representative of tissue fatty acid compositionthan is
plasma) and tests of cognition at baseline and at afuture time,
perhaps after 5 y. Because there may be a vascularcomponent to
Alzheimer disease, the background diet of any fish-oiltrial also
should be low in saturated fat and cholesterol (10).Alzheimer disease is so prevalent and so disastrous that definitiveclinical trials to delay or prevent it must be carried out.In
the meantime, because evidence exists that n3 fattyacids prevent
episodes of sudden death, the American Heart Associationhas already
recommended that all adults consume 2 fish mealsper week (11).
For people who are allergic to fish or who cannotobtain fish, we
suggest the consumption of one fish-oil capsule(1000 mg) per day.
The possibility that the fatty acids DHAand EPA in fish and fish oil
may delay the ravages of Alzheimerdisease is of great interest.
ACKNOWLEDGMENTS
Neither author had a personal or financial conflict of interest
with the 2 studies discussed or with the authors of those studies.
REFERENCES
Bird TD, Miller BL. Alzheimer's disease and other dementias.
In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, eds.
Harrison's principles of internal medicine. New York, NY: McGraw-Hill,
2005:2393406.
Connor WE. Importance of n3 fatty acids in health and
disease. Am J Clin Nutr 2000;71(suppl):171S5S.[Abstract/Free Full Text]
O'Connor DL, Hall R, Adamkin D, et al. Growth and development
in preterm infants fed long-chain polyunsaturated fatty acids: a prospective
randomized control trial. Pediatrics 2001;108:35971.[Abstract/Free Full Text]
Connor WE, Neuringer M, Lin DS. Dietary effects on brain fatty
acid composition: the reversibility of n3 fatty acid deficiency and
turnover of docosahexaenoic acid in the brain, erythrocytes, and plasma of
rhesus monkeys. J Lipid Res 1990;31:23748.[Abstract]
Sφderberg M, Edlund C, Kristensson K, Dallner G. Fatty acid
composition of brain phospholipids in aging and in Alzheimer's disease.
Lipids 1991;26:4215.[Medline]
Schaefer EJ, Bongard V, Beiser AS, et al. Plasma
phosphatidylcholine docosahexaenoic acid content and risk of dementia in
Alzheimer disease. Arch Neurol 2006;63:154550.[Abstract/Free Full Text]
van Gelder BM, Tijhuis M, Kalmijn S, Kromhout D. Fish
consumption, n3 fatty acids, and subsequent 5-y cognitive decline in
elderly men: the Zutphen Elderly Study. Am J Clin Nutr 2007;85:11427.
Beydoun MA, Kaufman JS, Satia JA, Rosamond W, Folsom AR.
Plasma n3 fatty acids and the risk of cognitive decline in older adults:
the Atherosclerosis Risk in Communities Study. Am J Clin Nutr
2007;85:110311.
Blok WL, Katan MB, van der Meer JWM. Modulation of
inflammation and cytokine production by dietary (n3) fatty acids. J Nutr
1996;126:151533.[Abstract/Free Full Text]
Oksman M, Hogyes IE, Amtul Z, et al. Impact of different
saturated fatty acid, polyunsaturated fatty acid and cholesterol containing
diets on beta-amyloid accumulation in APP/PSI transgenic mice. Neurobiol Dis
2006;23:56372.[Medline]
Lichtenstein AH, Appel LJ, Brands M, et al; American Heart
Association Nutrition Committee. Diet and lifestyle recommendations revision
2006: a scientific statement from the American Heart Association Nutrition
Committee. Circulation 2006;114:8296. Erratum published in Circulation
2006;114:e629.[Abstract/Free Full Text]
Related
articles in AJCN:
Plasma n3 fatty acids and the risk of cognitive decline in
older adults: the Atherosclerosis Risk in Communities Study
May A Beydoun, Jay S Kaufman, Jessie A Satia, Wayne Rosamond, and Aaron
R Folsom
AJCN 2007 85: 1103-1111. [Abstract][Full Text]
Fish consumption, n3 fatty acids, and subsequent 5-y cognitive
decline in elderly men: the Zutphen Elderly Study
Boukje Maria van Gelder, Marja Tijhuis, Sandra Kalmijn, and Daan
Kromhout
AJCN 2007 85: 1142-1147. [Abstract][Full Text]
DISCLAIMER:The information in HeatTreat.ca is not intended as a substitute for appropriate medical professional help or advice but is to be used as a sharing of new knowledge, information and as an aid to a new understanding about back and neck pain and its treatment. A trained, appropriate health professional should always be consulted for back pain or any health problem. HeatTreat.ca provides links to other articles and web sites as a service to our readers and is not responsible for the information, services, or products provided by these web sites, health professionals, or companies. See "Terms and
Conditions" for use of this Site